Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline

Inclusion Criteria:

1. Patients with 2018 FIGO staged IB1, IB2, IIA1 cervical cancer.

2. The initial treatment was radical hysterectomy + pelvic lymphadenectomy bylaparotomy or laparoscopy with cervical cancer foci sealed before dissection of thevagina and without uterine manipulator.

3. Postoperative pathological diagnosis was cervical squamous cell carcinoma, cervicaladenosquamous cell carcinoma or cervical adenocarcinoma.

4. Assessment of risk factors not meeting Sedlis criteria （NCCN guideline），but havingone of following factors ：（1）Deep stromal infiltration（≥2/3layer）；（2）histopathological differentiation grade G2 ~ G3；（3）Lymph-vascular spaceinvasion ；（4）Adenocarcinoma or adenosquamous cell carcinoma；（5）Tumor size ≥2cm.

5. Age：18-70 years old.

6. WBC≥3.510^9/L, NEU≥1.510^9/L, Platelet≥80×10^9 /L; AST and ALT ≤1.5 times normalupper limit; Total bilirubin ≤1.5 times the upper limit of normal value; serumcreatinine and blood urea nitrogen ≤the upper limit of normal value.

7. Eastern Cooperative Oncology Group score 0-1.

8. Well-compliance and willing to keep in touch.

9. Willing to participate in this study, and sign the informed consent.

Exclusion Criteria:

1. Postoperative pathology has high-risk factors（lymph node metastasis, parametrialinfiltration or positive surgical margin）or meets Sedlis criteria.

2. Participate in other clinical trials at the same time.

3. Comorbidity including but not limited to: heart diseases (grade III-IV cardiacinsufficiency (NYHA standard); central nervous system diseases or nonfunctionalbehavior; hematological system diseases; liver or kidney malformation or history ofsurgery.

4. Persons without disposing capacity.

5. Drug and/or alcohol abuse.

6. Unable or unwilling to sign informed consents.

7. Not eligible for the study judged by researchers.